A Bio-Superior
Drug Delivery System

Caisson Biotech has developed a heparosan-based drug delivery system using a patented composition designed to improve the performance of many powerful drug compounds in terms of safety, tolerability, efficacy and quality.

Market Need - Caisson’s Solution:
A novel non-toxic, stealthy vehicle for drugs

The pharmaceutical industry continues to search for safer, more effective solutions for delivering powerful drugs that have been developed through the years to combat cancer and numerous infectious diseases. These solutions are needed because the physical, chemical, biological and even toxic nature of some of these drug compounds prevent them from being delivered safely, cause unacceptable side effects, or are eliminated too rapidly by the body to be effective unless administered in large, multiple doses. In the 1980’s, drug companies began using an industrial polymer additive called PEG to counter these problems, and while effective, its use has serious shortcomings. Caisson Biotech has developed a heparosan-based system which adds a natural heparosan polymer vehicle to a drug cargo. Heparosan is a bio-superior substitute without the liabilities of the current $5.8 billion industry leading drug vehicle, PEG¹.

1. Kalorama Information Market Intelligence Report, 2005, Glycosylated Protein Therapeutics. Kalorama Information. New York, New York.